U.S. Government Purchases 1.4 Million Additional Antibody Cocktails

New York-based Regeneron Pharmaceuticals, Inc. announced today the U.S. Department of Defense and Department of Health and Human Services would purchase 1.4 million additional doses of the REGEN-COV (casirivimab and imdevimab) Antibody Cocktail at the cost of $2,100 per dose.

Under the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022. Regeneron expects to begin delivering the additional REGEN-COV doses in September, with the vast majority delivered in Q4 2021.

The U.S. government confirmed it would continue to provide REGEN-COV at no cost to patients.

"More than a year and a half into this pandemic, too many people are still being hospitalized and dying due to COVID-19," said Leonard S. Schleifer, M.D., Ph.D., President and CEO of Regeneron, in a related press statement.

"While vaccination remains the first line of defense to decrease the burden of COVID-19, REGEN-COV is a key tool that reduces the risk of hospitalization or death by 70% in high-risk individuals when given early in the course of the infection."

"Recently, there has been a greater demand for REGEN-COV, and we will provide additional doses to the U.S. government as quickly as possible."

REGEN-COV is an investigational medicine authorized by the U.S. FDA under an emergency use authorization to treat people at high risk of serious consequences from COVID-19 infection who are either already infected (non-hospitalized) or in certain post-exposure prophylaxis settings.

Regeneron (NASDAQ: REGN) is a leading biotechnology company located in Tarrytown, NY, that invents life-transforming medicines for people with serious diseases. Regeneron invented REGEN-COV and is collaborating with Roche to increase global supply, with Roche primarily responsible for development and distribution outside the USA.